cyrilzakka/clinical-trials huggingface dataset:
Short Term Surgical Outcomes of Anatomical Versus Non Anatomical Laparoscopic Liver Resection for Liver Tumors

aimed to discuss the short term surgical outcomes of Anatomical versus Non anatomical laparoscopic Liver resection for Liver tumors.

This study aimed to be both prospective and retrospective study including the cases of laparoscopic liver resection that was done and will be done during the period from December 2021 to June 2025. This study will include cohort of patients who met the eligible criteria.

Complete history taking with special concern to the following:

* Age, sex and life style.
* present medical history: hepatic condition and other debilitating diseases.
* Past medical History: blood transfusion, hepatitis, liver cirrhosis and history of hospital admission.

Complete local examination of the abdomen including:

* Local examination of the skin overlying for any signs of infection, radiation fibrosis and or presence of sinuses
* Percussion for presence of ascites
* Palpation for cirrhosis or any palpable masses investigations will be carried

  1. Ultrasonography: routine abdominal US for every case.
  2. Triphasic CT scan
  3. CT volumetric study to evaluate remaining liver volume when needed.
  4. Dynamic or triphasic MRI if needed
  5. Metastatic work up (CT chest, bone scan and PET scan in selected patients).
  6. Preoperative histopathological examination when needed.
  7. routine laboratory investigations

Eligibility Criteria:
Inclusion Criteria:

* all patients diagnosed with liver tumors (benign and malignant) lesions suitable for laparoscopic liver resection (Anatomical and Non anatomical)
* Patients with Child Pugh A and early B
* Patients Fit for surgery as regard anesthesia
* Patients who accept to participate in the study and sign an informed consent

Exclusion Criteria:

* Patients with Child Pugh late B\&C liver disease.
* For Patients with hepatocellular carcinoma BCLC stage C\&D (extra hepatic spread and macro vascular invasion)
* Patients with contraindications to laparoscopic surgery and (or) unfit for surgery.
Repeatability and Stability of Healthy Skin Features on OCT

A test-retest study on the stability and repeatability of healthy skin features on OCT


Eligibility Criteria:
Inclusion Criteria:

* At least18 years of age

Exclusion Criteria:

* Unable to sign informed consent
Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy

To study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer. To analyze the clinical significance of the concentration change of vascular endothelial growth factor (VEGF) in ascites in treatment of intraperitoneal injection bevacizumab


Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements.
* Histologically confirmed and documented ovarian cancer with malignant ascites.
* ECOG(Eastern Cooperative Oncology Group, ECOG) PS 0-2.
* Life expectancy of \>3 months.
* No serious inadequate bone marrow function, liver and renal function or significant cardiovascular disease.

Exclusion Criteria:

* Known hypersensitivity to any of the study drugs or excipients.
* Any current anti-cancer therapy.
* No evidence of ascites.
* Key organ dysfunction.
* Significant cardiovascular disease (e.g. congestive heart failure (CHF), uncontrolled cardiac arrhythmia, angina, heart valve disease, myocardial infarction and refractory hypertension need to be long time controlled by medicine).
* Non-healing wound, ulcer or bone fracture.
* Uncontrolled psychiatric history.
Pharmacokinetic Comparison of XS003 and Tasigna

The study will assess bioavailability of XS003 given as a single oral dose compared to Tasigna® given as a single oral dose in healthy male subjects.

The study consists of two parts, the first part is composed as a pilot part and compares the bioavailability of single oral doses of XS003 compared to Tasigna® given as single oral dose in healthy male subjects. The second part is a food-effect part which assesses the food effect of a single oral dose of XS003 in healthy male subjects either fed or fasted. The study will also evaluate safety and tolerability of XS003 as secondary objectives.

Eligibility Criteria:
Inclusion Criteria:

* Healthy males
* Age 18 to 55 years of age
* Body mass index (BMI) of 18.0 to 29.0 kg/m2
* Laboratory parameters in normal range

Exclusion Criteria:

* Females
* Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening.
* Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients.
* History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the investigator.
* Subject has a QTcF\>450 ms based on ECG at screening or a history of additional risk factors for Torsades de Pointe (e.g. hypokalaemia, hypomagnesemia, a family history of long QT syndrome)
Aging Brain Care Virtual Program

The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.


Eligibility Criteria:
Patient Inclusion Criteria:

* 65 and older,
* active primary care patient (visit in past 14 months),
* diagnosis of Alzheimer's disease and related dementias (ADRD) based on ICD criteria in primary care problems list.

Patient Exclusion Criteria:

* enrolled in hospice at the study start (study screening)or
* living in a long term care nursing facility.

Care Partners Inclusion Criteria:

* 18 and older,
* able to access a phone or computer for intervention delivery in English, and
* identified in the EMR as the emergency contact or as the primary care partner.

Care Partners Exclusion Criteria:

- Individuals who decline to participate in the ABCV intervention
IBD Registry in a Sub-Saharan African Population

The investigators intend to establish a prospective registry of patients diagnosed with inflammatory bowel disease at Parirenyatwa hospital in Harare, Zimbabwe. The study will periodically collect data on disease phenotype, disease course, and clinical management, and will biobank stool specimens and germline DNA. One relative, and an individual from the same neighbourhood will be also be recruited for a nested case-control study into risk factors of inflammatory bowel disease in this population.

A prospective observational registry with a nested case-control study will be established at a gastrointestinal outpatient's clinic at a tertiary care hospital in Harare, Zimbabwe. The registry will recruit confirmed cases of inflammatory bowel disease from the clinic, other hospitals within and outside Harare, and from private practitioners. Two controls, a sibling or cousin, and an individual living in the same neighbourhood will also be recruited for each case. Demographic and clinical data will be obtained for all cases at baseline, after 6 months and annually thereafter. A questionnaire adapted from the International Organisation of IBD for risk factors of inflammatory bowel disease, and a food frequency questionnaire will be administered to all participants. Stool specimens, and germline DNA from peripheral blood will be biobanked in the Department of Medicine at the University of Zimbabwe. Preliminary data analysis will be carried out after at least 100 patients have been recruited. Descriptive statistics will be used to summarise data on demographic and phenotypic characteristics of inflammatory bowel disease, and incidence will be estimated for Harare. Risk factors for inflammatory bowel disease will be analysed using conditional logistic regression.

Eligibility Criteria:
Inclusion Criteria:

* Cases

  1. Any patient with confirmed inflammatory bowel disease
  2. Onset of disease ≥3 months ago.
* Controls

  1. Age ≥ 18 years (NB - cases younger than 18 will be excluded from case-control analysis
  2. One sibling or cousin (2nd degree) and one neighbourhood control.

Exclusion Criteria:

* Cases

  1. None
* Controls

  1. Suspected inflammatory bowel disease
  2. Unexplained gastrointestinal symptoms including diarrhoea, vomiting, chronic abdominal pain, weight loss, rectal bleeding, and recent change in bowel habit.
  3. Previous unexplained gastrointestinal surgery
Study of Dronabinol Treatment for Depression and/or Anxiety in Older Patients

This is an observational study evaluating the safety and efficacy of dronabinol for the treatment of anxiety and/or depression in older adults. Participants who are prescribed dronabinol as part of a voluntary inpatient stay in McLean's Division of Geriatric Psychiatry will be interviewed about their mood and cognition on a weekly basis while on dronabinol.

Recently there has been renewed interest in potential alternative medical applications of cannabis/THC and medical marijuana is now legalized in 23 states and the District of Columbia. Acute effects of THC can include subjective feelings of euphoria, relaxation, and sedation, and clinicians noted that THC is well tolerated for its approved indications. Given these subjective effects and relatively benign safety profile, some physicians have used dronabinol (synthetic THC) "off-label" to treat depression and/or anxiety.

The investigators are doing this research to better understand how effective dronabinol treatment is when prescribed for depression and/or anxiety in older patients. The investigators also want to find out if dronabinol is safe to take without causing too many side effects. Dronabinol is is approved by the U.S. Food and Drug Administration (FDA) to treat loss of appetite in chemotherapy patients, but dronabinol is not approved by the FDA to treat depression and/or anxiety. Through research questionnaires on mood and cognition, the investigators can gather information that will help demonstrate how effective dronabinol treatment is at treating depression and/or anxiety.

Eligibility Criteria:
Inclusion Criteria:

1. 50-89 years old (inclusive)
2. Inpatient on the Older Adult Unit in South Belknap 1 at McLean Hospital
3. Initiating dronabinol therapy for the treatment of any Diagnostic and Statistical Manual (DSM) 5 Major Depression or Anxiety Disorder Diagnosis
4. Ability to provide informed consent
5. Must be fluent in English

Exclusion Criteria:

1. Delirium as determined by the Confusion Assessment Method (CAM)
2. Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease, which might confound assessment of safety outcomes
3. Seizure disorder
4. Diagnosis of bipolar depression, Major depression with psychotic features, schizophrenia, schizoaffective disorder, dementia
5. Use of dronabinol or marijuana in the last year
6. Prescription of lithium or anticonvulsant medications (except gabapentin)
7. Patient currently admitted involuntarily to McLean Hospital
Accuracy of Maxillary Repositioning With bi or Tripartite Disjonction by Virtual Planning in Orthognathic Surgery Using Patient-specific Titanium Plates

The aim of this study was to assess the accuracy of computer-aided orthognathic surgery and patient specific titanium plates for maxillar osteotomy with bi or tripartite disjonction in 22 patients who underwent bimaxillar osteotomy for occlusal trouble.


Eligibility Criteria:
Inclusion Criteria:

- bimaxillar osteotomy with maxillar segmentation and full imageries .

Exclusion Criteria:

None
Preoperative Anxiety Evaluation: a New Visual Smileys Scale

Preoperative anxiety is a complex clinical concept with both physiological and psychological consequences.

This study looks at the need for a more user friendly, rapid tool for measuring preoperative anxiety, specifically by evaluating the visual smileys scale.

Eligibility Criteria:
Inclusion Criteria:

* 18 to 80 years old
* undergoing surgery at Cedars Sinai Medical Center

Exclusion Criteria:

* did not receive sedative or narcotic prior to the interview
Evaluation of the Optimal Transition Program

This is an evaluation of a program developed by a team of nephrologists, operations experts and researchers. The goal is to provide CKD patients with a better way to transition to life on dialysis - one that emphasizes even more individual clinical, psychosocial and lifestyle needs. On top of high-quality clinical care, the 4-week Optimal Transition program supports patients as they adjust to treatment and learn to live the best life possible. This is done through a robust education curriculum and a trust-building approach.

In this program evaluation the investigators will be reporting on the following program outcomes:

1. Clinical and psychosocial stabilization: to include lab values, clinical dialysis parameters, patient-reported symptoms, quality of life, hospitalization and mortality rates.
2. Dialysis modality choice with satisfaction with the modality education and continued modality use over 24 months.
3. Patient knowledge, activation, and satisfaction.
4. Program parameters such as time, costs, referral rate, admissions and length of stay within the program.

Eligibility Criteria:
Inclusion Criteria:

* Referred for incenter hemodialysis at one of two Satellite Healthcare (SHC) participating dialysis units
* Without significant cognitive impairment;
* Able to meaningfully interact with staff; and
* Fluent in English (due to education material being limited to English at this time).

Exclusion Criteria:

* Unable to meaningfully interact with staff;
* Unable to read and understand English; or
* Has significant cognitive impairment per the nephrologist or Principal Investigator
Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease

The overarching question addressed in the current project is: Does dietary nitrate supplementation (8 weeks) improve physiological function in patients with peripheral arterial disease (PAD)? The investigators will specifically address whether dietary nitrate supplementation enhances blood vessel function, blood pressure regulation, and exercise capacity. The proposed project uses an array of clearly defined measurements which will allow investigators to quantify blood vessel function (vasodilator responsiveness and arterial stiffness), blood pressure (variability and responsiveness to stress), and functional capacity before and after 8 weeks of dietary supplementation.


Eligibility Criteria:
Inclusion Criteria:

* Documented peripheral artery disease
* Ankle-Brachial Index (ABI) \< or = to 0.90

Exclusion Criteria:

* Non-atherosclerotic vascular disease
* Critical limb ischemia
* Active ischemic ulceration
* Recent (within one year) revascularization
* Symptomatic coronary artery disease (angina pectoris)
* Heart failure
* Resting systolic blood pressure \> 180 mmHg or diastolic pressure \> 100 mmHg
* Hypotension (resting systolic BP \< 90 mmHg)
* Smoking or history of smoking within past one year
* Use of phosphodiesterase V inhibitor drugs
* Women with history of hormone replacement therapy within the past 6 months
Patient Profiling and Outcome Assessment in Spinal Cord Stimulation for Chronic Back and/or Leg Pain

The PROSTIM study is an ongoing prospective, multicentric and observational clinical study. Patients are recruited in three different centers in Eastern Belgium from May 2018 onwards. This real-world data collection approaches the outcome assessment of daily medical practice. A hierarchical cluster analysis is used to identify significant patient clusters based on the Visual Analogue Scale (VAS), Oswestry disability index (ODI), Pain Vigilance and Awareness Questionnaire (PVAQ), Pain Catastrophizing Scale (PCS) and EuroQol with five dimensions for health-related quality of life (EQ-5D). Patient clusters will be assessed on the change in biopsychosocial variables after six weeks, three and twelve months. Secondary outcomes include the comparison of pain medication use, SCS parameters, treatment satisfaction and return to work.


Eligibility Criteria:
Inclusion Criteria:

* Male/female over 18 years old.
* Chronic intractable back and/or leg pain (PSPS T2), refractory to conservative treatment measures.
* Positive recommendation after multidisciplinary assessment including psychiatric assessment.
* Patients are capable of giving written informed consent.

Exclusion Criteria:

* Negative recommendation after multidisciplinary assessment (ex. psychiatric disorders).
* Insufficient improvement during trial period.
* Previous SCS implantation.
* Removal due to complication (infection, loss of function,...)
* Surgical contraindication (infection of surgical site, coagulation disorders,..)
* Pregnancy.
Thromboelastography (TEG) In the Intrauterine Growth Restriction (IUGR) Neonatal Population by Gestational Age

The investigators aim to improve the understanding of TEG in this population in an effort to improve outcomes in a population at high risk in both the presence and absence of blood product transfusions.

The investigators plan to 1.) examine dynamic hemostasis as measured by TEG in the intrauterine growth restriction (IUGR) neonatal population due to a high risk of requiring blood transfusions, 2.) determine the influence of gestational age on TEG in this population, and 3.) examine the utility of TEG as a tool for identifying coagulopathy in IUGR neonates.

The investigators hypothesize that thromboelastography parameters will change with gestational age in the IUGR population in a manner similar to non-IUGR populations and that neonatal comorbidities, maternal factors, and socioeconomic status will influence TEG values; TEG is likely a useful marker of dynamic hemostasis in this neonatal subpopulation.

Eligibility Criteria:
Inclusion Criteria:

Participants included for medical record data and blood sample collection will be:

* Neonates diagnosed with intrauterine growth restriction, defined as a weight below the estimated 10th percentile and accordingly identified as such in any peripartum evaluation AND
* May have additional comorbidities AND
* Full term IUGR neonates will be have a gestational age of 37 weeks or greater OR
* Preterm IUGR neonates will have a gestational age less than 37 weeks OR
* Preterm IUGR neonates will have a gestational age less than 37 weeks

Participants included for medical record review data collection ONLY will be:

Mothers of eligible neonates

Exclusion Criteria:

* Constitutionally (familial) low birth weight, i.e. small for gestational age, babies OR
* Born to women with life threatening coexisting morbidities (this may include severe pre-eclampsia, diabetes or suspected infections including HIV or herpes) OR
* Neonates with an abnormal delivery or perinatal course including:

Fetal demise, death in the first week after birth, neonatal encephalopathy, meconium aspiration, and physical birth injuries (fractures and brachial plexus injuries)
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis

The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment in addition to Standard of Care (SoC) treatment.


Eligibility Criteria:
Inclusion Criteria:

* The subject has given written consent to participate in the study.
* Diagnosed previously with UC (\> 6 months earlier) determined by clinical and endoscopic histopathology (pathology showing chronic inflammatory changes). ≥1 documented previous flare-up and with last resolved flare \>3 months away.
* Active UC determined by sigmoidoscopy before randomisation of study (baseline) and defined as a total Mayo index score of 4 to 10 points (endoscopic subscore ≥1, rectal bleeding ≥1).
* Permitted concomitant SoC medications include: Oral aminosalicylates (5-ASA), with a stable dose (1.6-4.8g/ day) for at least 12 days prior to screening, Visit 1. Steroids (dose ≤15mg at screening, Visit 1) with further tapering of dose in accordance with SoC until steroid tx termination. Immunomodulator, as: 6-Mercaptopurine, Azathioprine, Methotrexate (Stable dose for \> 12 weeks prior to screening, Visit 1).
* Females of childbearing potential must use effective contraceptives

Exclusion Criteria:

1. Involvement in any investigational drug or device study within 30 days prior to this study
2. Known intolerance of 5-ASA or sulphasalazine medications
3. Biologics or FMT treatment less than 12 weeks before screening
4. No 5-ASA or steroid topical treatment is allowed
5. Antibiotic treatment \< 1 month prior the study
6. Unable to maintain stable dose of NSAIDs and PPIs
7. Evidence of on-going extensive colitis
8. Fever, defined as a temperature of \>38.5 °C, at Visit 1
9. Anaemia, Hb value below 100
10. Evidence of on-going toxic megacolon
11. Presence of obstructive diseases of the gastrointestinal system
12. Any clinically significant concomitant disease that might interfere with patient safety
13. Unwilling to withdraw probiotic supplements. Yoghurts without supplemented bacteria are permitted
14. Pregnant
15. Planned abdominal surgery
16. Judged unable by the physician to comprehend information regarding the study
Therapeutic Efficacy in Women With Stress Urinary Incontinence

We will get the impact of duloxetine versus imipramine on therapeutic efficacy in women with SUI.

Background/Purpose: Pharmacologic treatments for female stress urinary incontinence (SUI) include duloxetine and imipramine. Duloxetine and Imipramine has been reported to have clinical significant therapeutic efficacy on female SUI and overactive bladder syndrome. However, there was no randomized controlled study to compare duloxetine and imipramine for the treatment of female SUI.

Patients and Methods: We will perform a prospective randomized controlled study to recruit 90 female SUI patients at the Obstetrics \& Gynecology outpatient clinic of Far Eastern Memorial Hospital. All SUI female patients will be asked to complete ICIQ-UI, USS, OABSS, and bladder diary before and after 4 weeks' duloxetine versus imipramine treatment.

Eligibility Criteria:
Inclusion Criteria:

* Female patients over 25 years old with stress urinary incontinence.
* Patients who are currently not considered for surgical treatment.
* Patients who have undergone regular Kegel exercises but have poor results.

Exclusion Criteria:

* The result of urodynamic examination, if the main cause of urinary incontinence is detrusor overactivity.
* Those who are taking or plan to take monoamine oxidase inhibitor (MAOI) inhibitors.
* Patients with acute myocardial infarction.
* Those who are allergic to duloxetine, imipramine and dibenzazepine tricyclic antidepressants.
* Patients with uncontrolled narrow-angle glaucoma.
* Pregnant women.
* Those who are contraindicated to duloxetine or imipramine.
* Patients with suicidal ideation and behavior.